Equations and codes for the PBPK model
The equations below, along with the parameters in Table S1a-b, specify the PFOS PBPK model. The same equations are used in the PBPK model code provided below.
Uptake and elimination
The uptake of PFOS administrated via oral gavage was described using a twocompartment gastrointestinal (GI) model. After oral administration of PFOS into the stomach, PFOS enters the small intestine with a rate defined by the gastric emptying time (GE, 1 st order rate constant, h -1 ). Uptake from the stomach was described using a first-order rat constant, k0c, while the first-order rate constant Kabs (h -1 ) was used to describe the uptake of PFOS in the small intestine (h -1 ). PFOS absorbed from the GI tract is transported to the liver through the portal vein. PFOS administrated intravenously enters directly into systematic circulation. The equations are provided and explained below: RST = Rinput -K0c*AST -GE*AST (S1) RSI = GE*AST -Kabs*ASI -Kunabs*ASI (S2)
Where Rinput is the rate of oral administration of PFOS (mg/h); AST is the amount of PFOS in the stomach (mg); Kunabs is the rate constant of unabsorbed PFOS to appear in the feces (h -1 ).
A first-order urinary elimination rate, Kurine, was used to describe the excretion of PFOS from the filtrate compartment via the urine. Similarly, a first-order biliary excretion rate, Kbile, was used to account for PFOS excreted into the feces via the bile. The amount of unabsorbed dose to appear in the feces was described using first-order constant, Kunabs. The Equation
S4
-S5 describing the process of first-order urinary and fecal excretion processes: Rurine = Kurine*Afil (S4) Rfeces = Kbile*AL + Kunabs*ASI (S5)
Where Rurine and Rfeces are the urine and fecal elimination rates of PFOS (mg/h), respectively; Afil (mg) is the amount of PFOS in the filtrate compartment; AL (mg) is the amount of PFOS in liver.
Transport in the kidney compartment
The derivation of Michaelis-Menten parameters based on the in vitro to in vivo extrapolation was used to describe the active transport of PFOS by basolateral and apical membrane transporters in the proximal tubule cells as described in Worley and Fisher (2015) Due to the lack of data of PFOS, the activity of transport of PFOS was assumed the same with the consequence of PFOA. Measured Vmax for uptake of PFOA mediated by organic anion transporters Oat1 and Oat3 (Vmax_baso_invitro) was translated to in vivo value describing uptake of PFOS (Vmax_baso) by multiplying with a relative activity factor (RAFbaso) and an estimated mass of PTCs (protein). Similarly, the Vmax for Oatp1a1 was calculated from in vitro studies (Vmax_apical_invitro) and then translated to in vivo value (Vmax_apical) by multiplying the relative activity factor (RAFapi) and protein. The transporters in the kidney compartment are defined as Equations S6-S12:
where the RKb and RCl are the rates of change in the amount of PFOS in kidney blood and filtrate compartments (mg/h), respectively; Rdif is the diffusion rate from kidney to PTCs (mg/h); RA_baso is the rate of PFOS transport from the plasma to PTCs through basolateral transporters (mg/h); Cfil is the concentration of PFOS in the filtrate compartment (mg/L); CKb is the concentration of PFOS in the kidney plasma; RAefflux is the efflux rate of PFOS from PTCs back into the systemic circulation (mg/h). The transport rates of basolateral (RA_baso) and apical transporters (RA_apical) were described by Michaelis-Menten equations. The amounts of PFOS in the kidney plasma (Eq. S10), filtrate (Eq. S11) and PTCs (Eq. S12) compartments were obtained by integration of the rate Equations S1-S9. 
PBPK model parameters and baseline values

Preliminary calibration analysis
Several chemical-specific parameters whose initial values were obtained from the literature for PFOA were needed to be calibrated with experiment data for PFOS. A preliminary sensitivity analysis (SA) for the PBPK model parameters was performed based on the literature values to select sensitive parameters prior to calibration. The purpose of the SA was to compare and select sensitive PBPK parameter to be included in subsequent calibration analysis, starting with the likely sensitive parameters to reduce the computational burden and improve the performance quality. The preliminary sensitivity analysis and subsequent calibration were conducted using R package "FME" (Brun et al., 2001; Soetaert and Petzoldt, 2010) . Table S2a monkey and human models.
Estimation of posterior parameters
Convergence diagnosis
Four Markov chains of 500,000 iterations each, for the mouse, rat, monkey and human models, respectively, were run with the first 250,000 iterations as "burn-in" iterations and the last 50,000 iterations were used as output iterations to check convergences. Corrected Scale
Reduction Factors (R � ) were calculated for the four chains to diagnose the convergences of Markov chains based on the method of Brooks and Gelman (Brooks and Gelman, 1998) , and
Brooks-Gelman multivariate shrink factor (MPSRF) were used to assess whether the independent MCMC chains have converged to a common distribution. The R � and MPSRF values of population mean (µ) and population variance (∑ 2 ) in the mouse, rat, monkey and humans are provided in Table S3a -d.
Markov chains trace plots
The Markov chains trace plots and its probability density function plots are shown in Figs. S1-S8, which provide a visualization of the Markov chains' convergences. Specifically, a trace plot for the four chains plots the observed chain value (y-axis) against the corresponding iteration number (x-axis). The density plot for the four chains plots the observed chain value (x-axis) against density (y-axis).
Posterior parameter sensitivity analysis
A local sensitivity analysis was performed to determine which posterior parameters were most influential on the AUC of plasma, liver and kidney concentrations of PFOS in the mouse (single oral dose to 1 mg/kg/day), rat (daily dosing to 1 mg/kg/day for 98 days), monkey (daily dosing to 0.75 mg/kg/day for 182 days) and human (daily dosing to 4.5 ng/kg/day for 25 years).
Each of posterior parameters was increased by 1%, and the corresponding AUC of PFOS concentrations were estimated using Equation S13 (Lin et al., 2011; Mirfazaelian et al., 2006) as shown below:
where r is the response variable, and Δr is the change of the response variable resulting from 1% increase in the parameter value, p is the original value of the parameter of interest, Δp is 1% of the original value of the posterior parameter. The relative influence of each parameter on the response variables was categorized as: low: |NSC|<20%; medium: 20%≤|NSC|<50%;
high: 50%≤|NSC| (Lin et al., 2013; Yoon et al., 2009 ).
Model evaluation
The in vivo toxicokinetic datasets in mice, rats, monkeys and humans was searched and a few studies that were not included in previous PBPK modeling studies were identified (Fabrega et al., 2014; Kim et al., 2016) . The selected toxicokinetic studies for the PBPK model calibration, optimization, and evaluation are listed in Table 1 . Key in vivo studies are described with more details below:
Mouse
Due to limited datasets in the mouse, all datasets were used for the mouse model development (i.e., calibration and optimization). Two datasets from the same study (Chang et al., 2012) were used for the model calibration and optimization. In this study, the CD-1 male and female mice were administered PFOS as a single oral dose of 1 or 20 mg/kg. At designated times (2, 4, 8 hours and 1, 8, 15, 22, 36, 50, 64 and 141 days) post-dosing, four mice/sex were sacrificed and blood, kidney, and liver samples were obtained. Only male data were used in our study. The comparisons of the mouse experimental data and model predictions are shown in 
Rat
Three oral data sets from 3M unpublished studies (extracted from Loccisano et al. (2012)) with single oral doses (2 and 15 mg/kg) and daily oral dosing (1 mg/kg for 28 days), and the single oral dose studies from Kim et al. (2016) (2 mg/kg) and Chang et al. (2012) (4.2 and 15 mg/kg) were used to develop the PFOS PBPK model for the male rat. In addition to the oral studies, two single IV studies from Johnson et al. (1979) (single IV of 4.2 mg/kg) and (single IV of 2 mg/kg) were included for the model development. Moreover, the model was validated against a dietary dosing study (0.5, 2, 5, and 20 ppm for 14 weeks) from Seacat et al. (2003) . This study provided exposure information including weekly changes in body weights and food intakes of the rat, allowing incorporation into the model for independent evaluation. The comparisons of the rat experimental data and model predictions are shown in Fig. S10 . The independent evaluation result is shown in Fig. 5 .
Monkey
Two toxicokinetics datasets for PFOS in cynomolgus monkeys via IV and oral dose routes were used to develop the monkey PBPK model and for model evaluation (Chang et al., 2012; Seacat et al., 2002) . The IV dataset is described in details in Chang et al. (2012) . In brief, male and female monkeys (n = 3/sex) were administrated a single IV dose of 2 mg/kg PFOS and then monitored for 161 days after dosing. PFOS concentrations were measured in the plasma and urine of the monkey at several time points (2 -161 days). Another dataset used for model optimization was from a subchronic toxicity study of PFOS from Seacat et al. (2002) . In this study, male and female monkeys received daily oral dosing (by capsule) of 0.03, 0.15, 0.75 mg/kg PFOS for 26 weeks. The animals at the 0.15 and 0.75 mg/kg dose groups were allowed to recover for a year. Serum PFOS concentrations were measured throughout the dosing period for all the dose groups, and also during the recovery period for the 0.15 and 0.75 mg/kg dose groups. The liver PFOS concentration was used for model evaluation from the same dataset (Seacat et al., 2002) . The comparisons of the monkey experimental data and model predictions are shown in Fig. S11 . The independent evaluation result is shown in Fig. 5 .
Human
The human PFOS toxicokinetic datasets were relatively limited. There were no timecourse data with unknown exposure information available in humans, thus only one dataset (Haug et al., 2009) was considered in our model calibration and optimization. From Haug's study, the PFOS concentrations were measured in 57 pooled archived human serum samples in the period from 1976 to 2007 (Haug et al., 2009) general population from another PBPK modeling study (Loccisano et al., 2011) , and thus were applied in our model. In terms of independent data, only sparse datasets (i.e. only one or a few time points per exposure scenario) from epidemiology studies (Olsen et al., 2003a; Olsen et al., 2003b; Olsen et al., 2008) and human autopsy (Fabrega et al., 2014) were available. The human serum PFOS concentrations were measured using samples from the general population from
Red Cross adult donors in six cities around U.S. (N=600) from 2000 -2001 to 2006 (Olsen et al., 2003a Olsen et al., 2008) . Consisting with the assumption of previous PBPK modeling study (Loccisano et al., 2011) and estimated in the study of Olsen (Olsen et al., 2003a; Olsen et al., 2008) , the constant exposure doses were assumed to be the range of 0. The liver PFOS concentration data were collected from International Institute for the Advancement of Medicine (Olsen et al., 2003b) , and only the male data (n= 16, age range 5-74) were used in the present study. In addition, the PFOS concentrations in target organs from an autopsy were also used to evaluate the model (Fabrega et al., 2014) . However, the detailed exposure information was not available in the human autopsy study. In the human autopsy study, the exposure dose was assumed to 0.0018 µg/kg/day (Domingo et al., 2012) . Based on the previous report (Haug et al., 2010) , food is the major exposure source of PFOS (about 88% -99%). Thus, all datasets were simulated assuming to be oral exposure. The comparisons of the human experimental data and model predictions using the final optimized parameters are shown in Fig. S12 . The model evaluation was shown in Fig. 5 . Brown et al. (1997) 5 The baseline value was assumed to be 10% of the kidney volume (Worley et al., 2017) 6 Calculated based on 60 million PTCs/g kidney tissue (Hsu et al., 2014) 7 All baseline values are from Addis et al. (1936) 8 Baseline values are from Qi et al. (2004) (mouse), Corley et al. (2005) (rat, human) and Iwama et al. (2014) (monkey) 9 The baseline values of the mouse, rat and human were collected from Yang et al. (2015) ; the value for the monkey was collected from Fisher et al. (2011) * Calibrated values were refitted from the baseline values with experiment data for each species using the Levenberg-Marquardt algorithm. 1 The baseline values were assumed to be the same as PFOA in rats from Worley and Fisher (2015) and in humans from Worley et al. (2017) . The baseline values of mice and monkeys were assumed to be equal to rats and humans, respectively. Johnson et al., 1979 and Chang et al. 2012 (details provided in the Methods section above).
Supplementary Tables
Fig. S11
Comparisons of the PFOS PBPK model predictions for monkeys with experimental data from (A-B)
IV and (C-E) daily oral dosing studies in Cynomolgus monkeys. The experimental data (black dots)
are from Chang et al. (2012) and Seacat et al. (2002) . In the plot A and B, the circle symbols represent plasma data and the triangle symbols represent urine data. In the plot C, D and E, there are three dosing groups treated with 0.03 (circle), 0.15 (triangle), 0.75 (square) mg/kg/day PFOS for 26 weeks. Animals in the dosing groups of 0.15 and 0.75 mg/kg were allowed to recover for one year. 
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Additional files and instructions
Additional files
The additional files include several separate zip files: Code.zip, Datasets.zip, and Results.zip.
• Code.zip file: R codes for model calibration and MCMC optimization in the mouse, rat, monkey and human are included in this zip file.
-Model fitting & Optimization: The R code for model fitting and MCMC simulation.
-Mrgsolvecode-Mouse/Rat/Monkey/Human: The R code for mrgsolve-PBPK model code.
• Datasets.zip file: All datasets used in model calibration and optimization for the mouse, rat, monkey and human are included in this zip file. Please refer to Table 1 "Rat" folder:
-A1: The dataset from Chang et al. (2012) . Single oral dose (4.2 mg/kg); Matrix: plasma.
-A2: The dataset from 3M unpublished data. Single oral dose (2 mg/kg); Matrix: plasma.
-A3: The dataset from Kim et al. (2016) . Single oral dose (2 mg/kg); Matrix: plasma.
-A4: The dataset from Johnson et al. (1979) . Single iv dose (4.2 mg/kg); Matrix: urine.
-B1: The dataset from 3M unpublished data. Single oral dose (15 mg/kg); Matrix: plasma.
-B2: The dataset from Chang et al. (2012) . Single oral dose (15 mg/kg); Matrix: urine.
-B3: The dataset from Kim et al. (2016) . Single iv dose (2 mg/kg); Matrix: plasma.
-B4: The dataset from 3M unpublished data. Daily oral dose (1 mg/kg) for 4 weeks; Matrix: plasma.
"Monkey" folder:
-A1: The dataset from Chang et al. (2012) . Single iv dose (2 mg/kg); Matrix: plasma.
-A2: The dataset from Chang et al. (2012) . Single iv dose (2 mg/kg); Matrix: urine.
-B1: The dataset from Seacat et al. (2002) . Daily oral dose (0.03mg/kg) for 26 weeks; Matrix:
plasma.
-B2: The dataset from Seacat et al. (2002) . Daily oral dose (0.15 mg/kg) for 26 weeks; Matrix:
plasma. Table 4 .
-Code for Fig. S1 -S8: The R code used to generate results in Fig. S1 -S8.
-Code for Fig. S9 -S12: The R code used to generate results in Fig. S9 -S12. "Workplace" folder:
-.obs.rds: The ".rds" file containing all observed data for the mouse, rat, monkey and human.
-.MCMC.rds: The "rds" file containing all results of MCMC simulations for all species.
-.comb.rds: The "rds" file containing the simulation results of four Markov chains.
-theta.Rat.rds: The "rds" file containing the calibrated values for parameters.
-PBPK.rds: The "rds" file containing the PBPK-mrgsolve code.
Instructions on the model code
This instructions can be separated into three parts, including Part I: model development, Part II: model optimization using MCMC; and Part III: reproducing all figures and tables in the manuscript. The instructions below are presented using the Rat model as an example.
• Open the supplementary files: unzip all zip files  open the folder "Code" select the "Rat" file  open the R files "mrgsolvecode-Rat" and "Model fitting & Optimization-Rat" using Rstudio.
• Set your working directory: Set your working directory as the folder "Data for Rat" under the folder "Datasets".
• Run the mrgsolve code: Run all the code in "Mrgsolvecode-Rat" r file to compile the PBPK model. • Lines 1-14: loading required R packages
• Line 19: building the mrgsolve-based PBPK model ( you need to make sure that you have run all codes in "mrgsolvecode-Rat" R file)
• Lines 30-43: input the data sets for model calibration (you need to make sure that you have set the working directory as the folder "Data for Rat" under the folder "Datasets")
• Lines 45-199: run the code in lines 45-199. The best-fitting parameters will be generated and saved in the "Fit" object. Using the function "exp(Fit$par)" to check the values of the best-fitting parameters.
• Lines 201-205: to check the fitting results
• Lines 208-247: plot the time-course profiles for the calibration data, the plots are saved in plot.A1, plot.A2, plot.A3, and plot.A4.
Part II: Model optimization with MCMC (Code 250-592)
• Lines 258-269: input the optimization datasets
• Lines 275-313: input the parameters
• Lines 319-435: define the maximum likelihood function
• Lines 439-485: define the prior distribution function
• Lines 487-517: parallel computing + MCMC simulation
• Lines 519-525: convergence diagnosis for four Markov chains (each of the four chains has 500,000 iterations). The point estimate results represent the R � ratio results.
• Lines 528: save the posterior parameters (population mean and variance)
• Lines 531-537: convergence plots
• Lines 542-545: save the MCMC results as .rds files. "Rat.MCMC.rds" is the result of the posterior parameter values from 50,000 iterations.
• Lines 548-592: Plot the time-course profiles for the optimization data, the plots are saved in plot.B1, plot.B2, plot.B3, and plot.B4. The $bestpar shows the combination of best values for all parameters (i.e., this combination of parameter generates the best fitting results). These values are the final optimized parameter values that were used to generate results in Fig. 5 .
Part III: Reproducing all figures and tables presented in the manuscript
• Open the folder "Results". The folder includes two files "Code for plots" and "Workplace". The folder "Code for plots" stores all r codes for generating results presented in the figures and tables in the manuscript. The "Workplace" folder stores the MCMC simulation results for all species, which are saved as different ".rds" files. Please refer to the above for detailed explanation of each ".rds" file.
• Set the working directory as the folder "workplace" before running each figure or table code file.
• Open one of the r codes under the folder "Code for plots" and run it to reproduce the results presented in the figures and tables in the manuscript.
